Slow-Coagulation Cyclophotocoagulation Versus Conventional Continuous Wave Cyclophotocoagulation and Micropulse Cyclophotocoagulation for the Treatment of Glaucoma: A Systematic Review and Meta-Analysis
- 16 March 2026
- journal article
- review article
- Published by Wolters Kluwer Health in Journal of Glaucoma
- Vol. 35 (7) , 485-492
Abstract
Précis: SC-TSCPC significantly lowers intraocular pressure more effectively than MP-TSCPC and performs similarly to CW-TSCPC. Safety and visual outcomes are comparable, supporting its use as a nonincisional treatment option for various glaucoma patients. Introduction: Slow-coagulation transscleral cyclophotocoagulation (SC-TSCPC) is an emerging laser modality for glaucoma management designed to lower intraocular pressure (IOP) with possible fewer complications than conventional continuous-wave (CW-TSCPC) and micropulse (MP-TSCPC) approaches. We conducted a systematic review and meta-analysis to compare the efficacy and safety of SC-TSCPC with those of MP-TSCPC and CW-TSCPC. Methods: PubMed, Embase, and Cochrane Library were searched from inception through December 2025 for studies comparing SC-TSCPC with MP-TSCPC or “conventional” CW-TSCPC. Primary outcomes were IOP reduction from baseline and IOP at last follow-up. Secondary outcomes included medication burden, best-corrected visual acuity (BCVA), treatment success, and complications. We computed mean differences (MDs) for continuous endpoints and risk ratios (RRs) for binary endpoints, with 95% CIs. Results: Thirteen studies comprising 992 patients were included. SC-TSCPC achieved greater IOP reduction from baseline compared with MP-TSCPC ( MD 1.29 mm Hg, 95% CI 0.26–2.32, P =0.01, I 2 =0%) but was comparable to conventional CW-TSCPC ( MD -1.00 mm Hg, 95% CI −3.14 to 1.13, P =0.36). IOP at last follow-up, number of medications, BCVA, treatment success, and total complication rates for SC-TSCPC were similar to those for MP-TSCPC or CW-TSCPC. Conclusion: SC-TSCPC may provide comparable IOP control to CW-TSCPC and appears more effective than MP-TSCPC in lowering IOP, with a similar safety profile. It may represent a viable nonincisional treatment option for glaucoma, including patients who retain visual potential. These results require cautious interpretation due to the overall low-to-very low quality of evidence and significant heterogeneity among studies. Larger randomized studies are needed to validate these findings.Keywords
This publication has 35 references indexed in Scilit:
- Micropulse versus Slow Coagulation Transscleral Cyclophotocoagulation in Refractory GlaucomaOphthalmology Glaucoma, 2025
- Long-Term Treatment Outcomes of Micropulse Transscleral Cyclophotocoagulation in Primary and Secondary Glaucoma: A 5-Year AnalysisOphthalmology and Therapy, 2024
- Outcomes of slow coagulation transscleral cyclophotocoagulation in a predominantly African American glaucoma populationAmerican Journal of Ophthalmology Case Reports, 2024
- Treatment Outcomes in the Primary Tube Versus Trabeculectomy Study after 5 Years of Follow-upOphthalmology, 2022
- Cyclodestructive Procedures in Glaucoma: A Review of Current and Emerging OptionsAdvances in Therapy, 2018
- Transscleral Diode Laser CyclophotocoagulationOphthalmology Glaucoma, 2018
- Retrospective review on the outcome and safety of transscleral diode laser cyclophotocoagulation in refractory glaucoma in Chinese patientsInternational Ophthalmology, 2017
- Global Prevalence of Glaucoma and Projections of Glaucoma Burden through 2040Ophthalmology, 2014
- GRADE guidelines: 3. Rating the quality of evidenceJournal of Clinical Epidemiology, 2011
- Long-term Outcome of Initial Ciliary Ablation with Contact Diode Laser Transscleral Cyclophotocoagulation for Severe GlaucomaOphthalmology, 1996